These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35291351)

  • 1. Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings.
    Akinci B; Subauste A; Ajluni N; Esfandiari NH; Meral R; Neidert AH; Eraslan A; Hench R; Rus D; McKenna B; Hussain HK; Chenevert TL; Tayeh MK; Rupani AR; Innis JW; Mantzoros CS; Conjeevaram HS; Burant CL; Oral EA
    Med; 2021 Jul; 2(7):814-835. PubMed ID: 35291351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
    Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
    Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
    Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
    J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
    Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
    J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
    Diker-Cohen T; Cochran E; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 20 years of leptin: leptin in common obesity and associated disorders of metabolism.
    DePaoli AM
    J Endocrinol; 2014 Oct; 223(1):T71-81. PubMed ID: 24973357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice.
    Abulizi A; Perry RJ; Camporez JPG; Jurczak MJ; Petersen KF; Aspichueta P; Shulman GI
    FASEB J; 2017 Jul; 31(7):2916-2924. PubMed ID: 28330852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
    Tchang BG; Shukla AP; Aronne LJ
    Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
    Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
    J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G; Akinci B
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
    Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
    Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptin decreases de novo lipogenesis in patients with lipodystrophy.
    Baykal AP; Parks EJ; Shamburek R; Syed-Abdul MM; Chacko S; Cochran E; Startzell M; Gharib AM; Ouwerkerk R; Abd-Elmoniem KZ; Walter PJ; Walter M; Muniyappa R; Chung ST; Brown RJ
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
    Nguyen ML; Sachdev V; Burklow TR; Li W; Startzell M; Auh S; Brown RJ
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4327-e4339. PubMed ID: 34223895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
    Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
    Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA
    Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
    Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
    Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function.
    Bruder-Nascimento T; Kress TC; Belin de Chantemele EJ
    F1000Res; 2019; 8():. PubMed ID: 31656583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for leptin-replacement therapy for severe lipodystrophy.
    Oral EA; Chan JL
    Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metreleptin: first global approval.
    Chou K; Perry CM
    Drugs; 2013 Jun; 73(9):989-97. PubMed ID: 23740412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptin replacement therapy in the management of lipodystrophy syndromes.
    Vigouroux C; Mosbah H; Vatier C
    Ann Endocrinol (Paris); 2024 Jun; 85(3):201-204. PubMed ID: 38871500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.